This brand name is authorized in Japan.
The drug MIKELUNA contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
4797W6I0T4 - CARTEOLOL HYDROCHLORIDE
|
|
Carteolol is a non-selective beta-adrenergic blocking agent with associated intrinsic sympathomimetic activity (ISA) and without significant membrane stabilizing activity. Carteolol reduces normal and elevated intraocular pressure whether or not accompanied by glaucoma. |
|
2
|
UNII
6Z5B6HVF6O - LATANOPROST
|
|
The active substance latanoprost, a prostaglandin F2α analogue, is a selective prostanoid FP receptor agonist which reduces the intraocular pressure (IOP) by increasing the outflow of aqueous humour. Reduction of the IOP in man starts about three to four hours after administration and maximum effect is reached after eight to twelve hours. |
|
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| JP | 医薬品医療機器総合機構 | 1319823Q1026 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.